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A B S T R A C T
Fighting against risk factors for disability and dependency throughout the whole life process and – more
speciﬁcally relevant to this paper – during the second part of life, needs to become a core focus of adult
public health actions. In order to engage positive actions towards this goal, it is important to identify and
target modiﬁable risk factors. One would imagine that it is always possible to positively modify
‘‘intermediate’’ risk factors, such as health habits (sedentary lifestyle and diet), health behaviours
(alcohol consumption, smoking or other addictions. . .), as well as living and working conditions, and
access to healthcare. However, the simplest interventions of all could target ‘‘proximal’’ risk factors that
closely relate to disease and disability, such as hypertension, metabolic disorders (malnutrition and
diabetes), mood and cognitive impairments, musculoskeletal disorders, inappropriate drug prescriptions
and frailty. A careful review of the world literature allows to identify the most effective and efﬁcient
medical interventions allowing to prevent or delay these disabling clinical conditions and allow to reach
the WHO goal of ‘‘healthy ageing’’, which is developing and maintaining the functional ability that
enables well-being in older age.
 2016 Published by Elsevier Masson SAS.
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www.sciencedirect.com‘‘Prevention is not well understood, probably because its
challenges are not well understood’’
Jean-Franc¸ois Mattei
1. Introduction
One of the main challenges facing medicine in these early years
of 21st century is the foreseen ageing of the world population [1],
and more speciﬁcally, the increase in the number of years spent in
disability [2]. These assertions are consolidated by the1st World
Health Organisation (WHO) global report devoted to ageing
(2015), which deﬁnes healthy ageing as a ‘‘process of developing
and maintaining the functional ability that enables well-being in
older age’’ [3]. As stated by WHO general director Margaret Chan in
the preface of the report, ‘‘healthy ageing is more than just the
absence of disease; the maintenance of functional ability has the
highest importance’’ [3].
The ‘‘healthy ageing’’ pathway corresponds to a lifelong process.
After conception, the ﬁrst and second parts of life appear to have
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Building and maintaining intrinsic capacity, and living in
functional independence within our own surroundings until the
end of life is the most favourable outcome [3].
Fighting against risk factors for disability and dependency
throughout the whole life process and – more speciﬁcally relevant
to this paper – during the second part of life, needs to become a
core focus of adult public health actions. In order to engage
positive actions towards this goal, it is important to identify and
target modiﬁable risk factors. Indeed, it is not yet possible to
modify ‘‘non-controllable’’ risk factors, such as genetics, gender,
ethnicity, intellectual quotient or family background [4]. It is also
difﬁcult (albeit not impossible) to hope to change ‘‘distal’’ risk
factors, such as economic background, socio-cultural determi-
nants, education, air pollution, or exposure to noise or the sun.
One would imagine that it is always possible to positively modify
‘‘intermediate’’ risk factors, such as health habits (sedentary
lifestyle and diet), health behaviours (alcohol consumption,
smoking or other addictions. . .), as well as living and working
conditions, and access to healthcare. However, the simplest
interventions of all could target ‘‘proximal’’ risk factors that
closely relate to disease and disability, such as hypertension,
metabolic disorders (malnutrition and diabetes), mood and
cognitive impairments, musculoskeletal disorders, inappropriate
drug prescriptions and frailty [4].
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ageing, it would appear essential to demonstrate that interven-
tions focusing on lifelong health habits and behaviours, as well as
on ‘‘proximal’’ risk factors during the second part of life could
improve functional capacity or delay disability in old age.
2. Interventions focused on health habits and health
behaviours
Interventions focussing on health habits and health behaviours
are based on ‘‘health promotion’’. This is a lifelong process that
gives people the means to control and promote their own health. It
is never too late to adopt new life habits, as shown below.
2.1. Advantages of physical exercises and sport activities during the
second part of life
Self-reported walking difﬁculty, not linked to disability, was
found to increase the risk of overall (HR = 1.74 [95% CI 1.71–1.74])
and cardiovascular mortality at 10 years (1.98 [95% CI 1.95–2.02])
in a Finnish cohort of male Second World War veterans [5]. A study
of physical activity in US adults showed that exercisers performed
consistently better on the long distance corridor walk over 8 years,
and had greater aerobic ﬁtness compared to inactive or lifestyle
active participants [6]. Similarly, an English observational study of
3454 adults aged 63.7  8.9 years at inclusion with 8 years follow-
up, reported that taking up physical activities, even at an older age,
has positive physical, functional and mental repercussions (P values
ranging from > 0.005 to 0.001), compared to participants who
remained sedentary [7].
Clearly, regular, reasoned and reasonable physical exercise and
sport activities throughout one’s life, even those started at midlife,
have multiple positive beneﬁts and minimal disadvantages in the
ﬁght against the ‘‘sedentary death syndrome’’ [8].
2.2. An adapted diet at midlife greatly modiﬁes health
It is now well established that a Mediterranean diet has
signiﬁcant beneﬁcial effects on 10-year incidence of metabolic
syndrome, diabetes, hypertension and inﬂammatory markers
[9]. The Predimed randomized trial, which included 7447 volun-
teers aged 55 to 80 years at high cardiovascular risk, demonstrated
that a Mediterranean diet supplemented with extra-virgin olive oil
or nuts signiﬁcantly reduced major cardiovascular events after a
median follow-up of 4.8 years [10]. In a separate analysis from the
same study, compared to a low-fat control diet, a Mediterranean
diet supplemented in extra-virgin olive oil or mixed nuts
signiﬁcantly slowed cognitive decline, as assessed by the MMSE
and clock drawing tests [11].
In summary, involuntary weight loss at midlife is a risk factor
for mortality, while obesity at the same time period increases
cardiovascular risk. This latter risk could be controlled by physical
exercise and a Mediterranean diet supplemented in virgin olive oil
or nuts, leading to a reduction or mitigation of clinical conditions
causing disability.
2.3. Non-smoking adults have a greater chance of living longer,
healthier lives
At the world level, between 1965 and 2014, passive and active
smoking caused more than 20 million premature deaths (10 million
from metabolic, cardio-, neuro- and reno-vascular events and
6.9 million from respiratory diseases) [12]. Moreover, it was
recently shown that mid-life and late-life smokers had a
signiﬁcantly greater risk than lifelong non-smokers of developingall-cause dementia (adjusted hazard ratio (aHR) = 2.28 [95% CI
1.49–3.49]), vascular dementia (aHR = 2.88 [95% CI 1.34–6.20])
and Alzheimer’s disease (aHR = 1.98 [95% CI 1.09–3.61]) [13]. In-
deed, many diseases caused by tobacco smoking have a negative
impact on daily functioning.
To ﬁght against this scourge, the WHO has proposed to prohibit
tobacco advertising, to protect non-smokers, promote education
and help to increase the numbers of those who quit smoking. The
World Bank has also reported that increasing the price of tobacco
by 10% resulted in a 4% decrease in global tobacco sales, and an 8%
decrease among the youngest smokers [14].
Without doubt, abstaining from smoking is the single lifestyle
habit that offers the greatest protection against cardiovascular,
neurological and renal vascular events, as well as respiratory
diseases, and consequently, against their negative functional
repercussions in daily life.
2.4. Light or moderate alcohol consumption does not make you live
longer
Studies focused on life course trajectories of alcohol consump-
tion are scarce. However, an analysis of 9 English studies
demonstrated that 2 peaks of alcohol consumption exist, namely
young, and pre-retired adults [15]. In France, 37% of adults aged
18 to 74 years are considered to have an at-risk level of alcohol
intake [16]. The possible positive effect of light to moderate alcohol
consumption on longevity was completely rejected by the Pianoro
study. This 6-year follow-up of 5256 community-dwelling adults
aged > 65 years from Northern Italy (2318 abstainers and
2309 light to moderate drinkers at  2 alcoholic drinks per day)
showed that when adjusted for physical activity and self-reported
health, light to moderate alcohol consumption had no direct
protective effect on mortality [17]. On the contrary, harmful effects
of moderate to heavy alcohol consumption appear at midlife,
mainly in the form of acute cardiovascular and neurological events
[18].
It is therefore essential to recall that a long-term or midlife
sedentary lifestyle, malnutrition, tobacco smoking and moderate
alcohol consumption are all avoidable health scourges that
negatively affect health and functional capacity, and precipitate
death. The key new message is that randomized controlled studies
have shown that it is never too late to reap the positive beneﬁts of
controlling these deleterious life habits.
3. Interventions focused on diseases that increase both
disability and mortality
Two main groups of chronic diseases that can increase both
disability and mortality deserve to be targeted. The ﬁrst group is
composed of diseases that not only increase mortality, but in case
of survival, will also be the cause of disability. The second group
comprises classical geriatric diseases that do not directly bring on
death, but do increase disability. A third and often-neglected issue,
namely adverse effects of drugs and inappropriate prescriptions,
also need to be addressed.
3.1. Life course vaccination program
The 2013 WHO report stated that currently, worldwide,
vaccines annually prevent more than 2.3 million deaths from
communicable diseases [19], which perfectly explains the decrease
observed in worldwide communicable diseases, from 33% of all
deaths in 1990 to 25% in 2010 [20]. However, there is a striking
imbalance between the burden of preventable infectious diseases
in US older adults compared to US children [21], reﬂecting the
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vaccination programs, as well as the resurgence and changing
patterns of common vaccine-preventable diseases across the
different age strata [22,23]. By stimulating immune memory
responses, vaccines administered early in life can usually provide
long-term, if not lifelong immunity against many vaccine-
preventable diseases [24]. In addition, in 2006, the American
Heart Association and American College of Cardiology recommen-
ded inﬂuenza vaccine as part of secondary prevention in persons
with coronary and other atherosclerotic diseases [25]. It has been
shown that inﬂuenza vaccination within-season was associated
with a 24% decrease in stroke risk [26]. Herpes zoster vaccine in
young adults appeared to cause varicella zoster vasculopathy
explaining myocardial infarction, stroke and transient ischemic
attack appearing up to 6 months after the clinical features of the
disease [27,28]. Herpes zoster vaccine could probably prevent the
viral multiplication into the arterial walls and reduce the dramatic
consequences of the disease.
In old adults, the expected beneﬁts of vaccine are enormous,
with decreased mortality and disability linked to preventable
infectious diseases, reduced complications and hospitalizations,
reduced antibiotic use and antibiotic resistance, while at the same
time, being cost effective [29].
3.2. Midlife interventions on cardiovascular, neurological and renal
disease
In case of long-term survival after any acute events, cardiovas-
cular, neurological and renal diseases can be the cause of
restrictions on activity and engagement in society for the
individual. For each of these medical conditions, it is important
to target midlife or potentially reversible risk factors and
demonstrate that prevention is active and useful, even late in life.
Cardiovascular and neurological diseases, which are highly
prevalent in people aged over 70, are the primary cause of
morbidity and mortality. Among the modiﬁable risk factors for
these diseases are a sedentary lifestyle, smoking, high-salt diet
[30], overweight, hypertension, diabetes [31], kidney failure [32],
hypercholesterolemia and also depression and sleep apnoea
[33,34], and even non-steroidal anti-inﬂammatory drugs (NSAIDs)
[35]. Controlling these main risk factors is essential, as demon-
strated by the Whitehall study, a 38-year longitudinal study
including 19,019 male civil servants aged between 40 and 69 at
their ﬁrst examination on inclusion in the study between 1967 and
1970 [36]. In this study, it was shown that an adult of 50 years who
smokes and is both hypertensive and hypercholesterolemic has a
reduction of 10 years in life expectancy. If at the same time this
patient is obese and diabetic, the life expectancy will be reduced by
15 years [36]. Arterial hypertension is also a major risk factor
[37]. The Three-City (3C) study demonstrated in 7612 adults over
65 years of age presenting with no cardiovascular disease at
inclusion that after 5.2 years of follow-up, metabolic syndrome
was associated with signiﬁcant risks of fatal (HR: 2.40; 95% CI
1.41–4.09) and non-fatal coronary heart disease events (HR: 1.64;
95% CI 1.24–2.17) [38].
On the positive side, a randomized controlled trial testing the
effectiveness of dietary guidelines among 162 non-smoking men
and women aged 40 to 70 years showed that compared to controls
(n = 80), after only 12 weeks, the group with strict application of
dietary guidelines (n = 82) had a signiﬁcant decrease in body
weight (–1.9 kg, P < 0.001), daytime systolic blood pressure
(–42 mmHg, P < 0.001), the total/HDL cholesterol ratio (–0.13,
P = 0.044) and high sensitivity C-reactive protein (–36%, P = 017)
[39]. In a Canadian study, a health educator-led heart-health
intervention to help family members of patients with coronary
artery disease to better understand cardiovascular risk factors, andset dietary and life habit goals, appeared to signiﬁcantly favour a
healthier diet and the level of physical activity [40]. Even in very
old age, control of arterial blood pressure reduces both mortality
and morbidity, as shown by the Hyvet study in adults with a mean
age of 83 years. In this population, active treatment was associated
with a reduced rate of neurological and cardiovascular death
(P = 0.05 and P = 0.06, respectively), and a 64% reduction in the rate
of heart failure (95% CI, 42–78; P < 0.001) [41].
Therefore, even in mid- to late-life, interventions focusing on
cardiovascular, neurological and renal risk factors remain possible,
and have been proven beneﬁcial in terms of the duration and
quality of survival.
3.3. Midlife prevention of diabetes
Diabetes is a silent disease. Indeed, one in ﬁve diabetic patients
between the ages of 18 and 70 is not diagnosed. The peak prevalence
of diabetes is beyond the age of 74, reaching 15% in women and 20%
in men. Risk factors for diabetes are well established, and include
low socio-economic status, sedentary lifestyle, overweight, high
waist circumference, hypertension and depression. It was shown in
a group of 290 hyperglycemic patients that compared to controls, an
intervention in midlife targeting life habits (i.e. a 5% decrease in
bodyweight among overweight patients, and an increase in physical
activity) signiﬁcantly delayed the appearance of diabetes, whose
annual incidence was 5.1 per 100 participants in the control group,
vs. 2.3 per 100 participants in the intervention group (P < 0.04)
[42]. Unfortunately, a US study of an intensive lifestyle intervention
promoting weight loss and increased physical activity had to be
interrupted after a median follow-up of 9.6 years for futility. Overall,
at the study end, the lifestyle intervention produced greater weight
loss, reduced glycated haemoglobin, and greater initial improve-
ments in ﬁtness and all cardiovascular risk factors, but without
reaching statistical signiﬁcance [43].
Diet and lifestyle interventions, even later in life, have been
shown to be effective in delaying progression of diabetes. However,
poor compliance may explain the disappointing long-term results
obtained with such programmes.
3.4. Prevention of chronic respiratory diseases
Asthma often occurs along the life cycle starting from early
childhood [44], and affecting 30 million children and adults under
the age of 45 years in Europe [45]. Chronic Obstructive Pulmonary
Disease has an estimated annual death rate of over 3 million people
globally [44,46]. There is an urgent need to understand, prevent,
detect and manage these diseases across the life cycle [47],
particularly in older people, and their socio-economic impact at
the global level also deserves to be investigated.
In Finland between 1994 and 2004, a structured national
asthma program including earlier diagnosis and active treatment,
implementation of simple guidelines, organization of collaboration
between primary care and specialists, development of local asthma
physician, nurse and pharmacist networks and patient-centered
asthma education and empowerment (guided self-management)
resulted in signiﬁcant reductions in asthma morbidity, hospital
admissions, disability pensions and costs [48]. Other successful
results of national asthma programs have been published from
around the world [49].
The AIRWAYS ICPs initiative (Integrated care pathways for
airway diseases) [50] has been approved by the European
Innovation Partnership on Active and Healthy Ageing as the model
of chronic diseases of the B3 Action Plan. It is a GARD (Global
Alliance against Chronic Respiratory Diseases, WHO) Research
Demonstration Project with a speciﬁc focus on old age adults in
AIRWAYS ICPs.
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4.1. Midlife prevention of cognitive decline and dementia
Four out of ﬁve women over the age of 85 suffer from dementia.
Apart from ageing, the modiﬁable risk factors for dementia are well
known, namely low educational attainment (HR: 1.59 [95% CI
1.35–1.86]), less than 30 minutes of physical activity per week
(HR: 1.82 [1.19–2.78]) and at midlife, smoking (HR: 1.59 [1.15–
2.20]), hypertension (HR: 1.61 [1.16–2.24]), obesity (BMI > 30 kg/
m2) and diabetes (HR: 1.46 [1.20–1.77]) [51].
The impact of these different risk factors on cognitive decline
has been widely investigated. A longitudinal study by the Mayo
clinic investigating the interaction between basic education and
professional responsibility among 1995 ApoE4-negative adults
aged 50 to 65 years, showed that cognitive decline was signiﬁ-
cantly greater in participants with low education and without
professional responsibility [52]. A meta-analysis of 15 prospective
studies including 33,816 adults aged > 65 years who were
cognitively intact at inclusion, showed that after a mean follow-
up of 5 years, intense or moderate physical activity signiﬁcantly
reduced cognitive decline, testifying that physical activity is an
excellent means to prevent or delay dementia [53]. The multi-
domain randomized ‘‘Finger’’ trial combining better diet, physical
activity and control of cardiovascular risk factors in 1260 adults
aged 60 to 77 years demonstrated a reduction in cognitive decline
in the intervention group, although the participants had more
muscular side effects (7%) [54]. Similarly, the longitudinal
community-based Framingham Heart study performed between
1948 and 2014 on participants of the ﬁrst cohort (n = 5209), their
children (n = 5214) and grandchildren (n = 4201) showed that
stroke multiplies the incidence of dementia by 2. Moreover, it was
reported that 12% of participants without any clinical features or
suspicious stroke event had vascular lesions on MRI, which could
also lead to cognitive decline or dementia [55].
The constant enhancement of cognitive reserve and the
prevention of cardiovascular risk factors, notably through physical
exercise, are keys to delaying cognitive decline and onset of
dementia.
4.2. Midlife prevention of musculoskeletal diseases
4.2.1. Osteoporosis
Age-related osteoporotic clinical expression in women depends
greatly on post-puberty level of peak bone mass, which is in turn
related to genetics, but also diet (calcium intake), exposure to the
sun (vitamin D), and physical activity during the ﬁrst period of life
[56]. Later in life, menopause provokes a considerable decrease in
bone mass, which is aggravated by numerous factors, such as low
weight, anorexia, a voluntarily restrictive diet, a sedentary
lifestyle, a deﬁcit in calcium or vitamin D, smoking, alcohol
consumption as well as potential diseases and their speciﬁc
treatments (e.g. corticosteroids). The accumulation of these risk
factors compounds the decline in bone mass, exceeding the
fracture threshold. Indeed, the control of modiﬁable risk factors is
essential in order to reduce their negative repercussions on bone
and fall risks [57].
A meta-analysis of 10 studies focusing on the effect of physical
activities on fracture risk in elderly patients showed promising
evidence of a positive effect (relative risk for fractures in the
physically active group = 0.49, 95% CI [0.31–0.76]), although the
possibility of publication bias could not be ruled out [58]. In
addition to exercise, a diet including whole milk, whole dietary
products, water enriched in calcium and fat ﬁsh, and supplemented
in calcium (1200 mg/day) and vitamin D (800 to 1200 IU/day), is thebest method of preventing osteoporosis. Numerous drugs with
proven beneﬁcial effects can also be used to the same end [59].
Secondary prevention after a ﬁrst fracture, based on a personal-
ized management program and including increased physical
activity, adapted diet and anti-osteoporotic medications, has also
been shown to be useful in preventing new trauma lesions [60].
4.2.2. Osteoarthritis
Osteoarthritis mainly affects women. By the age of 65 years,
65% suffer from osteoarthritis, and this rate rises to 80% by the age
of 80 years. Osteoarthritis is as complex disease that simulta-
neously affects the cartilage, chondral bone and synovium, and
includes a local or systemic inﬂammatory process [61]. The
modiﬁable risk factors of osteoarthritis include metabolic dis-
orders (mainly obesity) and excess pressure and constraints
(overweight, bearing heavy loads, excessively intense physical or
sport activities). Secondary osteoarthritis can occur in relation
with anatomic abnormalities (e.g. dysplasia, varus, valgus), post-
traumatic lesions (e.g. fractures, sprains, dislocation), surgery
(speciﬁcally meniscectomy), or in association with numerous
diseases, such as osteonecrosis, chondrocalcinosis, hemochroma-
tosis, or rheumatoid arthritis [59].
Prevention is mainly based on weight loss in case of obesity, as
well as regular, moderate and progressive physical activity
(outside of acute inﬂammatory ﬂares), and avoiding heavy lifting.
On the medical side, custom-made shoe inserts, other orthotic
devices or technical walking aids, as well as adaptation of the
patient’s surroundings are useful. Articular rest (outside of the
inﬂammatory ﬂares), physical rehabilitation, manual therapy and
possibly thermal bath therapy can also be proposed. Surgery is
usually required in case of anatomic abnormality. Long-term
medical therapy remains the subject of considerable debate [62],
although a single multicentre study reported that sulfate chondroitin
could reduce articular pain and control inter-articular damage [63].
4.2.3. Sarcopenia
The European Working Group on Sarcopenia in Older People
(EWGSOP) deﬁnes age-related sarcopenia as ‘‘a syndrome charac-
terized by progressive and generalized loss of skeletal muscle mass
and strength with a risk of adverse outcomes such as physical
disability, poor quality of life and death’’ [64]. The EWGSOP also
proposed diagnosing sarcopenia using the criteria of low muscle
mass and low muscle function (either low strength and/or low
physical performance) [64]. It was also determined that sarcopenia
could be either primary (age-related) or secondary (precipitated by
a sedentary lifestyle, under-nutrition, or disease-related) [64].
The International Sarcopenia Initiative analyzed all published
papers concerning interventions devoted to reversing sarcopenia
[65]. Among them, different resistance training programs appeared
to increase muscle strength more than muscle mass, and
surprisingly, the beneﬁt was more pronounced in older compared
to younger adults. Combining resistance training and nutritional
supplements yielded even more positive results by increasing
muscle strength, facilitating activities of daily living, and decreas-
ing bone mineral loss [65]. Dietary protein interventions using
various combinations and various durations were shown to favour
muscle mass and strength recovery as well as activities of daily
living. However, results suggested an additive effect of exercise
and nutrition interventions that remain to be further explored [65].
4.3. Midlife prevention of age-related sensory deﬁciencies
4.3.1. Vision
With increasing age, eyesight spontaneously deteriorates, with
an ensuing reduction of visual acuity and ﬁeld of vision, and
diseases, such as cataracts, macular degeneration, glaucoma and
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Health, Aging and Body composition study included 1862 partici-
pants aged 70 to 79 years, with no mobility limitation at baseline,
despite visual impairment (7.4% had impaired visual acuity, 27.2%
had impaired contrast sensitivity, and 29.2% had impaired
stereoacuity). At follow-up, visual impairment was associated
with walking limitations (HR = 2.0 [95% CI 1.6–2.5]) and stair
climbing limitation (HR = 2.1 [95% CI 1.6–2.8]) [66]. Without
appropriate care and correction, age-related visual impairments
can lead to a deterioration in posture, gait and balance, and thereby
increase the fall risk [67–69]. Addressing visual impairment can
help to limit negative repercussions on functional capacity.
4.3.2. Vestibular function
Visuospatial and vestibular skills are closely linked, as
demonstrated by a speciﬁc cross sectional analysis performed
within the Baltimore Longitudinal Study of Aging among
183 community-dwelling adults with a mean age of 72 years
[range 26–91]. Vestibular-evoked myogenic potentials and various
visuospatial cognitive tests were correlated to executive, memory
and attention tests, and showed that vestibular loss could be part
of the ﬁrst signs of dementia and Alzheimer’s disease [70].
4.3.3. Hearing
Age-related hearing impairments (tonal, sounds, vocal, word
repetition) contribute to isolation and cognitive decline [71]. The
Epidemiology of Hearing Loss Study, a 15-year longitudinal
population-based cohort study involving 1925 individuals aged
between 43 and 84 years, reported that the 15-year cumulative
incidence of hearing impairment (over 25 decibels in either ear)
reached 56.8%. Adjusted for age and gender, the most important
risk factors were waist circumference (HR: 1.08 per 10 cm), current
smoking (HR = 1.31) and poorly controlled diabetes (HR = 2.03).
These ﬁndings underline that targeting these risk factors may help
prevent or delay the onset of hearing impairment [72].
4.3.4. Age-related olfaction impairment
Dysosmia, hyposmia or anosmia are not frequently investigated
in clinical practice, but it is now recognized these impairments are
markers of cognitive decline [71].
Apart from non-controllable risk factors, modiﬁable risk factors
for sensory impairments are numerous and accumulate during the
life course, such as excessively intense exposure to the sun or to
noise, too rich a diet, a sedentary lifestyle, smoking, alcohol, air-
conditioning as well as hypertension, diabetes and certain drugs
(e.g. corticosteroids, antidepressants).
All these age-related functional abnormalities can contribute to
disturbed posture, balance and gait, and thus negatively impact
both on daily life and survival. Evidence from the MRC National
Survey of Health and Development in England, Scotland, and
Wales, involving 1411 women and 1355 men clearly illustrated
this point [73]. Participants in this study underwent assessment of
physical capability at age 53 (in 1999) using three objective
measures, namely grip strength, chair rise time, and standing
balance time, and all-cause mortality was recorded up to age 66
(2012). After adjustment for anthropometric measurements,
lifestyle and health status, the authors found that subjects in
the lowest quintile (worst performance) had lower socio-economic
status, more diabetes, cardiovascular and respiratory diseases, and
those who could not perform any of the tests had signiﬁcantly
increased rates of death compared with those who were able to
perform all three tests (HR 8.40, 95%CI 4.35–16.23) [73].
Taken together, all these ﬁndings highlight the interaction
between sensory connections and ageing, and the importance of
mid-life assessment of vision, hearing and olfaction, to identify risk
factors and slow age-related changes [57,68,69].4.4. Medications and their possible negative impact on age-related
dependency
Two contradictory aspects need to be taken into consideration
when considering the use of medications, and their possible
negative effects [74]. In real life, treatment compliance is
insufﬁcient for many diseases for which effective treatments exist
(40 to 70% for hypertension, 60% for diabetes, 50% for hypercho-
lesterolemia). On the other hand, polypharmacy (deﬁned as use of
more than four different drugs per day) appears to be very common
in aged persons. Four different community-based surveys with one
to seven years of follow-up demonstrated that polypharmacy
favors functional decline and dependency (P < 0.001) [75], while
prescription of benzodiazepines or anticholinergic drugs nega-
tively impacts on activities of daily living (P < 0.001) [75]. Similar-
ly, numerous drugs are known to provoke muscular lesions, such as
statins (which may be harmful when given in association ﬁbrates,
cloﬁbrate or amiodarone), anti-rhumatismal drugs, NSAIDS, or
antipsychotics [76].
Another major danger of medications in ageing or aged adults is
the potential for kidney failure. NSAIDs have been reported to be
responsible for acute kidney failure (adjusted rate ratio 2.30, 95% CI
[1.60–3.32]) [77]. Iodinated contrast agents induce asymptomatic
kidney failure in 0.1 to 13% of patients within 72 hours after any
radiological examination with injection. In most cases, this renal
insufﬁciency resolves spontaneously, however the abnormality
could also lead to the need for renal dialysis [78]. In a study of
8357 patients undergoing percutaneous coronary intervention,
Mehran et al. established a risk score for contrast-induced
nephropathy [79]. A score > 16 points was associated with
57.3% risk of contrast-induced nephropathy and 12.8% risk of
dialysis [79]. These data prove the need for careful clinical and
biological assessment before radiological examination using
contrast medium in ageing and aged patients, in order to avoid
kidney failure and the dependency inherent to requirements for
constraining and expensive care. Two preventive actions are
essential to prevent contrast-induced nephropathy in ageing
adults undergoing radiological examinations with contrast injec-
tion, namely rehydration and careful choice of the contrast agent
by the radiologist.
5. Interventions to delay or prevent the frailty process
Frailty is an age- or disease-related state of increased
vulnerability to poor resolution of homeostasis following a stress,
which increases the risk of adverse outcomes, including impaired
balance, falls, trauma, infection, increased drug use, hospitaliza-
tion, disability and mortality [80]. Preceded by a totally silent
intermediate phase (termed pre-frail), a frailty phenotype was
operationalized, and includes unintentional weight loss, self-
reported exhaustion, low energy expenditure, slow gait speed and
weak grip strength [81].
5.1. The potential ‘‘spontaneous’’ reversibility of the frailty pathway
An adapted version of Fried’s criteria for physical frailty [81]
was used by the SHARE study (Survey of Health, Aging and
Retirement in Europe), the largest observational survey to date
performed in Europe, including more than 85,000 individuals aged
65 or over from 19 countries across Europe and Israel [82]. In this
study, the prevalence of frailty reached 17%, varying from 5.8% in
Switzerland to 27.3% in Spain and the prevalence of pre-frailty was
considerably higher, ranging from 34.6% in Germany to 50.9% in
Spain [83]. The comparison of naturally occurring transitions
between the 2nd (2006) and the 4th (2011) waves of SHARE,
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frail or robust state deteriorates over time, as do the pre-frail and
frail states. Surprisingly, however, without known intervention,
pre-frail and frail states were reversible in more than one third of
the older adults studied, with transition towards the non-frail or
pre-frail states [84]. The spontaneous possible reversibility of
frailty was conﬁrmed by the Precipitating Events Project in the USA
involving 754 non-ADL-disabled community-living persons aged
70 years or older, followed from 18 to 54 months. Transitions to
lesser frailty (rates up to 23.0%) exist, even though they are less
frequent than transitions to greater frailty (rates up to 43.3%) [85].
5.2. Risks and protective factors associated with transitions in frailty
status
A two-year longitudinal study of 3018 Chinese community-
dwelling adults identiﬁed risk factors for transition between frailty
states in both genders. Older age, previous stroke or cancer,
osteoarthritis, lower cognition, chronic lung diseases and hospi-
talizations were all shown to be risk factors for decline. Conversely,
factors favouring improvement away from pre-frail or frail states
were lower age, higher MMSE and absence of stroke in men, and
lower age, higher economic status, absence of diabetes and no
hospitalization in women [86].
5.3. Results of randomized control trials to reverse the frailty pathway
The number of randomized controlled trials performed to
reverse the frailty process has escalated in recent years
[87]. Published data testify to the fact that protein-energy
supplementation alone [88–90] is less effective than physical
exercise alone [91–93], and each of these measures individually is
less effective than the combination of the two together [94]. The
most promising results in terms of frailty reversibility were
obtained by randomized controlled trials based on multidisciplin-
ary interventions targeting individual frailty components. Howev-
er, it appears that the use of classical outcome measures (Short
Physical Performance Battery test, Barthel’s index, or health
related quality of life) is less demonstrative [95] than more
targeted and personalized outcome evaluations (Goal attainment
scale, life space assessment or self-report measures of activity)
[96]. Currently, a number of trials focusing on multifactorial
interventions are ongoing [97–99], and their results will be a
welcome addition to the body of literature on this topic.
6. Concluding messages
To close this long review of interventions focused on medical
conditions that can cause functional inabilities, it is essential to
stress again that ageing is a lifelong process. Indeed, lifestyles and
behaviours across the life course (physical exercise, adequate
nutrition, low alcohol consumption and non-smoking) are
fundamental in order to foster functionally independent ageing.
In parallel, prevention of diseases that increase disability is
necessary and possible at any age. Findings from a number of
randomized controlled trials prove that interventions are truly
effective in preventing cardiovascular, neurological and renal
disease, diabetes, cognitive decline, osteoporosis and sarcopenia,
as well as sensory impairments. Targeting populations at-risk,
particularly during the second part of life, could help to delay or
prevent frailty and its major complications, and speciﬁcally
disability, which is the most important WHO target on ageing.
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